Prospera Financial Services Inc Has $11.02 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Prospera Financial Services Inc lowered its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 4.6% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 62,130 shares of the company’s stock after selling 3,027 shares during the quarter. Johnson & Johnson comprises 0.5% of Prospera Financial Services Inc’s holdings, making the stock its 21st biggest position. Prospera Financial Services Inc’s holdings in Johnson & Johnson were worth $11,021,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. Riversedge Advisors LLC raised its stake in Johnson & Johnson by 8.6% in the fourth quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock valued at $627,000 after purchasing an additional 289 shares in the last quarter. Insight Wealth Strategies LLC raised its stake in Johnson & Johnson by 22.0% in the fourth quarter. Insight Wealth Strategies LLC now owns 13,713 shares of the company’s stock valued at $2,346,000 after purchasing an additional 2,473 shares in the last quarter. Northstar Group Inc. raised its stake in Johnson & Johnson by 2.3% in the fourth quarter. Northstar Group Inc. now owns 45,522 shares of the company’s stock valued at $7,788,000 after purchasing an additional 1,004 shares in the last quarter. Ieq Capital LLC raised its stake in Johnson & Johnson by 3.6% in the fourth quarter. Ieq Capital LLC now owns 108,946 shares of the company’s stock valued at $18,637,000 after purchasing an additional 3,814 shares in the last quarter. Finally, Raymond James Trust N.A. raised its stake in Johnson & Johnson by 1.3% in the fourth quarter. Raymond James Trust N.A. now owns 173,776 shares of the company’s stock valued at $29,728,000 after purchasing an additional 2,281 shares in the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of analyst reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. UBS Group decreased their target price on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Finally, Raymond James lifted their target price on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $171.11 on Friday. The business’s 50 day simple moving average is $175.21 and its 200 day simple moving average is $174.55. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The stock has a market capitalization of $449.88 billion, a PE ratio of 24.91, a PEG ratio of 3.32 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.14.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same period in the previous year, the firm earned $2.48 earnings per share. The company’s revenue was up 3.0% compared to the same quarter last year. As a group, research analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.64%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Insider Buying and Selling at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.